×
BioCryst Pharmaceuticals EBITDA 2010-2024 | BCRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
BioCryst Pharmaceuticals ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
BioCryst Pharmaceuticals EBITDA 2010-2024 | BCRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
BioCryst Pharmaceuticals ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$76.9B
Takeda Pharmaceutical (TAK)
$43.9B
Merck (MKKGY)
$20.8B
Astellas Pharma (ALPMY)
$20.2B
Sandoz Group AG (SDZNY)
$19.6B
United Therapeutics (UTHR)
$17.7B
Summit Therapeutics (SMMT)
$15.4B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12.3B
Catalent (CTLT)
$10.9B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Orion OYJ (ORINY)
$6.8B
Ionis Pharmaceuticals (IONS)
$5.7B
Corcept Therapeutics (CORT)
$5.7B
Crinetics Pharmaceuticals (CRNX)
$4.7B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
Catalyst Pharmaceuticals (CPRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.2B
NewAmsterdam Pharma (NAMS)
$2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.8B
Harrow (HROW)
$1.7B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.6B
Ardelyx (ARDX)
$1.5B
ARS Pharmaceuticals (SPRY)
$1.5B